Review Article

Natural products: An emerging tool in parkinson’s disease therapeutics

Rohit R Doke\(^1\), Prajakta A Pansare\(^1\), Shivani R Sainani\(^1\), Vrushali M Bhalchim\(^1\), Ketki R Rode\(^1\), Shivani R Desai\(^1,\ast\)

\(^1\)Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, Maharashtra, India

ARTICLE INFO

Article history:
Received 03-08-2019
Accepted 27-08-2019
Available online 06-09-2019

Keywords:
Neurodegeneration
Natural products
Neuroprotective
Parkinsons disease
Phytoconstituents
Signalling pathways

ABSTRACT

Parkinson’s disease is a age associated chronic neurodegenerative disorder of central nervous system characterized by selective loss of dopaminergic neurons in substantia nigra pars compacta which causes functional impairment of midbrain. Although the cause of PD is still not known, but there are several factors such asoxidative stress, genetic mutations, mitochondrial dysfunction, aggregation protein specifically \(\alpha\)-synuclein and neuroinflammation play a pivotal role in pathogenesis of PD. The current treatment primarily includes dopaminergic and non-dopaminergic medications which only provides symptomatic relief and when drug therapy is fails to provide relief, the next step is surgical treatments. Unfortunately the current regimens have certain limitations with multiple side effects and possess economic burden thus, there is a need to discovered new therapeutic approaches which have antiparkinsonial potential and minimum adverse effects. For many years, some phytoconstituents from natural products have provided a competent resource for the revelation of potential therapeutic agents. The anti-PD potential of these phytoconstituents is because of their well apperceived anti-oxidative, anti-inflammatory activities, their repressive role on aggregation of protein and the regulatory effects of PD cognate pathways. The intention of this review article is to cover the potential of phytoconstituents against the neurodegeneration intangle in PD and to encourage the improvement in future novel treatment strategies predicated on natural sources.

© 2019 Published by Innovative Publication.

1. Introduction

Parkinson’s disease (PD) is age associated second most prevalent neurodegenerative disease of the central nervous system [First is Alzheimer’s disease (AD)] and mainly disturb the motor function of the human body).\(^1\) The incidence of Parkinson’s disease is less in early ages, but as the age increases the prevalence also increases rapidly. The incidence of PD is more in females than male.\(^2\) PD is first introduce by English surgeon James Parkinson who first described the syndrome which he called as the ‘shaking palsy’.\(^3\) Parkinson’s disease is characterised by the degradation of dopaminergic neurons in the SNpc (part of midbrain) leading to disability in normal movements.\(^4\) Apart from dopaminergic degeneration, genetic mutations and environmental factors are additionally plays paramount role in this disease.\(^5\) Lewy bodies are result of alpha-synuclein protein mutations, thereby contributing to the degeneration of dopaminergic neurons.\(^6\) In additament, mitochondrial dysfunction causes declination of ATP leading to declination of energy and also enhances reactive oxygen species (ROS), and both of these cause initiation of apoptotic pathways and consequent neuronal death.\(^7\) The neuro-inflammation which is initiated by ROS also plays crucial role for development of PD.\(^8\) The neurotoxins and cytokines released from the cells destroy the dopaminergic neurons in striatum and substantianigra.\(^9\) Neuro-inflammation occurring in the striatum and substantianigrakeads to behavioural and biochemical deficiency in PD.\(^10\) Apart from this, the several pathways which are proximately associated with development and progression of PD includes, the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt)\(^11,\ast\) signalling pathway (the nuclear factor erythroid2-cognate factor2 (Nrf2)
signaling pathway\textsuperscript{13,14} the P38 mitogen activated protein kinase (P38MAPK) signaling pathway,\textsuperscript{15,16} the glycogen synthase kinase-3b (GSK-3b) signaling pathway,\textsuperscript{17,18} the c-jun-N-terminal kinase (JNK) signaling pathway,\textsuperscript{19,20} the nuclear transcription factor-kB (NF-kB) signaling pathway,\textsuperscript{21,22} the Wnt signaling pathway\textsuperscript{23,24} and the autophagy lysosome pathway (ALP).\textsuperscript{25,26}

Slowness of movement, resting tremor, rigidity of muscles, joints and difficulties in both speech and writing are some of the disturbing motor symptoms of the said disorder\textsuperscript{27} whereas the non-motor symptoms of PD include neuropsychiatric disturbances, autonomic dysfunction, sleep disorders, gastrointestinal symptoms.\textsuperscript{28} All these symptoms decrease the quality of life of the patients in addition to reduction in daily functioning.\textsuperscript{29} While the causative factors of the disorder is difficult to deal with, the healthcare society has worked hard atleast ameliorate the difficulties and provide symptomatic relief by providing several pharmacological agents, such as L-dihydroxyphenyl alanine (L-DOPA), monoamine oxidase-B(MAO-B) inhibitors and Dopamine(DA) agonist are commonly used which are presently prescribe to the affected person according to the extent of need and survey of symptoms.\textsuperscript{30} As known from long term, L-DOPA which has been considered as gold standard for treatment of PD. A serious limitations in that it causes motor fluctuations, dyskinesia or both thereby enhancing symptomatic stress in the patient.\textsuperscript{31} Also other drugs that are prescribed along with L-DOPA are not so efficient as they cause confusion, hallucination and hepatotoxicity and fails to prevent dopaminergic neuro-degeneration and thus the progression of disease.\textsuperscript{32}

The current regimens are hindered by therapeutic inhibitions and with certain deleterious effects; thus, there is a desideratum to develop novel drugs having maximum efficiency and minimum adverse affects. hence to promote the development of future novel treatment strategies predicated on natural sources to fight neurodegeneration is the current aim of this review.

1.1. Pathogenesis of PD

Parkinson’s is a multifactorial neurodegenerative disease, and there are number of factors responsible for neurodegeneration in parkinsons disease.

1.2. Protein stability and aggregation in parkinson’s disease

Protein misfolding is a phenomenon caused of neurodegeneration where the normal protein structure changes to the 3-dimensionsal structure within the nerve cell.\textsuperscript{33} mutations in different genes like, \textit{SNCA}, \textit{PARK2}, \textit{PINK1}, \textit{DJ-1} and \textit{LRRK2} causes Protein misfolding and leading to affect neuronal function.\textsuperscript{34–36} Normally neurotrophic factors inhibit the Protein misfolding however it is reported that the neurotrophic factors have been reduced in the PD. Due to relative reduction of these growth factors, accumulation and aggregation proteins occurs, within a nerve cells.\textsuperscript{37} The abnormal aggregation of mis-folded proteins is also called as “Lewy Body” (LBs).\textsuperscript{38} The main component of LBs is alpha synuclein which is pronto misfolding and aggregation.\textsuperscript{39} The alpha synuclein is a protein involves in axonal transport, synaptic vesicle function, and neuronal plasticity.\textsuperscript{40} The genetic mutation, oxidative and nitrosative stress, mitochondrial dysfunction can influence aggregation and misfolding of synuclein in prototypi is, fibrils, and filaments.\textsuperscript{41} Anomalously aggregated protein affects ubiquitin proteosomal and chaperone mediated autophagic system which inhibit neuronal function and axonal transport.\textsuperscript{42} The alpha synuclein in LBs further leads to neurodegeneration by interfering with mitochondrial function, autophagy, vesicular homeos tasis and neuroinflammation.\textsuperscript{43}

1.3. Mitochondrial dysfunction

Mitochondria are the intracellular organelle which carry the biological oxidation and produces energy in mammalian cells and mainly function as energy generation in the form of adenosine triphosphate (ATP).\textsuperscript{44} Dysfunction of the mitochondria leads to the pathogenesis of PD. For example, environmental neurotoxin 1-methyl-4-phenyl-1,2,3,4 -tetrahydropyridine (MPTP) produces parkinsonism.\textsuperscript{45} MPTP is metabolised into toxic cation named 1-methyl-4-phenylpyridinium (MPP+) under the enzymatic action of MAO-B which further interferes with electron transport chain (ETC), ultimately causing mitochondrial dysfunction.\textsuperscript{46,47} Also, MPP+ is as an active substrate of the DA transporter and accumulates into dopaminergic neurons of the brain causing neuronal death.\textsuperscript{48} This phenomenon results in ROS generation with increased oxidative stress and decrease ATP production, also resulting in a high intracellular calcium concentration, nitric oxide (NO) and excitotoxicity-mediated neuronal damage.\textsuperscript{49} The decrease in ATP production leads to the UPS dysfunction resulting in an activation of pathways involved in aggregation and apoptosis.\textsuperscript{50} The initiation of the mitochondrial apoptotic pathways and release of pro-apoptotic proteins from the inter-membranous space including cytochrome C, that induce caspase-dependent cell death and apoptosis inducing factor (AIF) and endonuclease G that translocate to the nucleus and induce caspase-independent nuclear DNA fragmentation.\textsuperscript{51}

Chronic exposure of another neurotoxin rotenone causes inhibition of mitochondrial respiratory chain complex-I resulting into selective degeneration of dopamine neurons. Inhibition of complex-I activity, activation of astrocytes and microglial cells, inflammatory reaction, glutamate excitotoxicity and in creased nitrosative stress, nitric oxide
and malondialdehyde level, aggregation of α-synuclein are involved in the mechanism of rotenone-induced parkinsonism. Genetic mutations in mitochondrial DNA (mtDNA) result in mitochondrial dysfunction and the pathogenesis of PD. For example, in patients with PD, the mutation in maternally inherited 12SrRNA may result in a significant reduction of cytochrome oxidase activity which is an essential enzyme that maintains normal mitochondrial functioning. Thus, confirming the relationship between mitochondrial dysfunction and PD.

1.4. Oxidative stress

Whenever there is an imbalance between the production of reactive oxygen species (ROS) and the ability of the body to neutralize their harmful effects, it results in oxidative stress (OS). The excessive OS damages the cellular components like lipids, proteins and DNA. The primary site of ROS generation in brain is mitochondria of neurons and glia. Neuroinflammation, dopamine degradation, mitochondrial dysfunction, aging, GSH depletion, and high levels of iron or Ca2+ are leading cause for production of these free radicals. ROS production also observed presence of neurotoxin like Rotenone and MPTP. Releasing of dopamine from the vesicle into the cytoplasmic coordinate iron molecules (Fe) present in the brain which redox reactions that result in the formation of neuromelanine (NM) and reactive oxygen species (ROS). Neuromelanine will also coordinate Fe and produce ROS. α-synuclein is a protein which is responsible for regulation of equilibrium between vesicle bound and cytoplasmic dopamine. The mutations of this protein shift the dopamine equilibrium in favour of the cytoplasm. Presence of Fe and oxidative stress leads to aggregation of α-synuclein protein causing pigmentation of neurons which are more susceptible to damages. The overproduction of ROS causes mutation of PTEN-induced putative kinase-1 (PINK1) which is a protein expressed in human tissues which plays a critical role in the fighting against OS and maintaining mitochondrial membrane potential. Furthermore, complex-I deficiency caused by ROS leads to activation of certain apoptotic and pro-apoptosis factors and thus the neuronal death.

1.5. Neuroinflammation

The first evidence of involvement of neuroinflammation in PD pathogenesis has been reported by McGeer et al. in 1988, they have found that post-mortem brains of patients who had PD shows increased human leucocyte antigen-DR positive microglia. In addition to this study, it has been shown that there are increased pro-inflammatory mediators in the striatum and substantia nigra, including TNF, ILβ, IL6, iNOS and COX2. Microglia is one of the major types of cell which is involved in the inflammatory responses in the central nervous system. As discussed earlier, PD is a associated with abnormal aggregation of α-synuclein which further activates microglia. Oligomers of α-synuclein activates toll-like receptor 2 (TLR2)-mediated signaling which affects microglia. The characteristic features of neuroinflammation include activation of microglia, reactive astrocytes within the brain and release of various inflammatory mediators including cytokines (TNF-α, IL-1β, and IL-6), chemokines, complement cascade proteins, ROS and reactive nitrogen species (RNS). These factors are known to disrupt the BBB permeability. The specific association between these neuroinflammatory mediators and neurodegeneration remains unclear however, it is reported by Witte et al. that mitochondrial dysfunction and oxidative stress are central to this progression. They suggested that, altered mitochondrial function leads to impaired energy metabolism and induces neuroinflammation via NO and ROS production, which results in neurodegeneration.

1.6. Proteolysis defects

Non-functional and abnormal proteins are removed by three mechanisms: the autophagy-lysosomal pathway, the ubiquitin-proteasome system, and molecular chaperones. α-synuclein protein is mainly removed through this mechanisms. Inhibition of those mechanisms leads to accumulation of abnormal proteins that can misfold, aggregated and block the normal molecular pathways, leading to cell death. Mitochondrial and UPS functioning is normally regulated by genes namely PINK1, parkin, and DJ-1, UCH-L1 respectively. Mutation in these genes may turn into dysfunctions of mitochondria and UPS system which further leads to degeneration of DA neurons. Mutation in DJ-1 upregulate oxidative and nitrosative stress and thus causes dopamine oxidation. Alterations in mitochondrial function also triggers some major pathways which accelerates oxidative stress, α-synuclein aggregation and further leads to dopaminergic neurodegeneration in PD.
Fig. 1: Pathophysiology of parkinson’s disease.

Fig. 2: Current therapeutic management of PD.
Table 1:

| S. No. | Compound Name | Plant Source | Class                  | Mode of Action                                                                                                                                                         |
|--------|---------------|--------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1      | Baicalein     | Roots of *Scutellaria baicalensis* and *Scutellaria lateriflora* | Flavonoid              | Antioxidant, anti-inflammatory, inhibits α-synuclein aggregation                                                                                                       |
| 2      | Curcumin      | *Curcuma longa* | Polyphenolic flavonoids | Strong antioxidant activity, increased DA, DOPAC activity and decreased MAO-B activity, ↓ phosphorylation of JNK1/2 and c-Jun, ↓ caspase-3, and thus anti-apoptotic, Enhances autophagy and lysosome biogenesis by activating TFEB |
| 3      | Resveratrol   | *P. cuspidatum* | Polyphenols             | Reduce α-synuclein aggregation via autophagy induction, downregulation of a apoptosis-inducing factor (AIF) and upregulate Bcl-2 family protein (an anti-apoptotic protein), Reduce expression of COX-2 and tumor necrosis factor- α and inhibition of microglial activation |
| 4      | Ginkgolides   | *Ginkgo biloba* | Flavonoids and glycosides | Improved locomotor activity, superoxide dismutase (SOD), glutathione (GSH) and tyrosine hydroxylase (TH), BDNF level increase by increasing the levels of phosphorylated CREB Suppression of neuronal apoptosis through activation of the Akt pathway |
| 5      | Ginsenoside   | Plant *Panax ginseng*, Family *Araliaceae* | Steroidal saponins     | Decreasing the levels of apoptotic proteins like Bax, Bcl-2, cytochrome c, and cleaved caspase-3, Antioxidant effect by activating Nrf2 transcriptional factor, Allivates Neuroinflammation by supressing NF-KB pathway and inhibiting activation of reactive astrocytes and microglia, Neuroprotective effects via Wnt/β-catenin signaling pathway, Upregulation of PI3K/AKT/Nrf2 Pathway. |
| 6      | Bacosides     | *Bacopa monnieri* (Brahmi) Family *Scrophulariaceae* | Glycosides             | Attenuates behavioral deformities, reduces the oxidative stress and neuronal cell death Improving TH activity, improves locomotor activity and cognitive functions |
| 7      | L-DOPA        | *Mucuna pruriens* (MP) Family *leguminoseae* | Flavonoid              | Neuroprotection by reducing apoptotic (Bax and caspase-3) and increasing levels of anti-apoptotic protein (Bcl2) expression, Neuronal survival by improving mitochondrial and synaptic functions, increases TH expression, improves locomotion and other motor performance |

Continued on next page
| No. | Plant Name                                                                 | Family               | Compound Type       | Activity                                                                                                                                  | References |
|-----|---------------------------------------------------------------------------|----------------------|---------------------|------------------------------------------------------------------------------------------------------------------------------------------|------------|
| 8   | Silymarin                                                                 | *Silybum marianum*   | flavonolignans       | Antioxidant, Anti-inflammatory, cytoprotective and neuroprotective. Increase in DA and serotonin levels and secretions of trophic factors, prevents conversion of DA to DOPAC by MAO-B, downregulate synthesis of inflammatory mediators (TNF-α, TNF-β, iNOS, NO) and apoptotic proteins (p53 and apaf-1, caspase-9) | 130-136    |
| 9   | Gastrodin                                                                 | *Gastrodia elata*    | Glycosides           | Increased DA concentration and decreased DA turnover in striatum. Anti-apoptotic and Antioxidant activity, inhibit obstruct NF-κB signaling pathway and prevent phosphorylation of MAPKs thus inhibit release of cytokines. | 137-141    |
| 10  | Withanolides                                                              | *Withania somnifera* / *Ashwagandha* | Alkoloids           | Increasing GSH and glutathione peroxidase (GPx) level, TH positive cells and DA levels in striatum along with improved motor function. | 142-146    |
| 11  | Nicotine                                                                  | *Nicotiana tabacum*  | Alkaloids            | downregulated cell apoptosis signaling pathways. Inhibit a-synuclein fibrillation. Inhibit astrocytes and microglia activation in SNpc and increase GDNF in the striatum by Activation of a7 nicotinic acetylcholine receptor (a7-nAChRs) Improvs learning and memory Trigger pro-survival signaling pathway( Wnt/β-caten in, PI3K, Akt) | 147-155    |
| 12  | Triptolide                                                                | *Tripterygium wilfordii* | Terpenoid           | impedsmicroglial activation and thus attenuates neuroinflammation. promotes a-synuclein clearance by increasing level of LC3-II protein in autophagy pathway. | 156-158    |
| 13  | Puerarin                                                                  | *Pueraria lobata* (PL) | Flavonoid            | Increase TH positive neurons, and neurotrophic factor GDNF, protein expression of DJ-1 and superoxide dismutase-2, regulate PI3K/Akt signalling pathway | 159-162    |
| 14  | Magnolol                                                                  | *Plant Magnolia officinalis* | Phenylpropanoid  | anti-inflammatory property by down-regulating the expression of Toll like receptor 4 (TLR 40 and p38/ MAPK signaling pathway modulate PI3K-MEK-ERK pathway, PI3K-Akt-FoxO1 and promote neuronal survival. Increase DA and TH | 163-167    |
| 15  | Epigallocatechin--3-gallate                                               | *Camellia sinensis* belo | Polyphenols         | inhibits nuclear translocation of NF-Kb, a-synuclein fibrillation, Increases DA, decreases the TNF-α, nitrite level Modulate MAPKs, PI3K-Akt cell signalling pathways. | 168-171    |
Table 1 continued

|   |     |                  |            |                                                                 |
|---|-----|-----------------|------------|-----------------------------------------------------------------|
| 16| Paeoniflorin | *Paeonia lactiflora*, family-Paeoniaceae | Terpenoid | Induce autophagy by upregulation of LC3-II protein, also activates ubiquitin-proteasome pathway and promote sdegradation of a-synuclein, decreases mitochondrial membrane potential, ROS production and increases of Bax/Bcl-2 ratio, |
| 17| Ligustrazine and tetramethylpyrazine | *Ligusticum striatum* and *Ligusticum wallichii* Family-Apiaceae | Alkaloid | Enhance levels of antiapoptotic proteins and downregulate levels of apoptotic proteins, increase amount of phosphorylated Akt while decrease GSK-3β activity by Activation of PI3K/Akt/GSK3β Showing Pathway, upregulate the level s of SOD and GSH. |
| 18| Naringenin | tomatoes, grapefruits, | flavonoids | Shows antiapoptotic effects by inhibiting phosphorylation of JNK and P38, and activation of caspase-9, PARP, and caspase-3 Restores the levels of protecive proteins parkin, DJ1, TH, Nrf2 and thus improves antioxidant status |
| 19| Crocin | *Crocus sativus* Family: Iridaceae | Caretonoids | Caretonoids improve aversive memory through antioxidant and anti-inflammatory potential. attenuate cholinergic function reduce α-synuclein aggregation and fibrillation. inhibition of apoptotic dark neuron formation and inflammatory factors. increased GSH GPX, SOD and CAT activity. anticholinergic |
| 20| Hyoscyamine | Hyoscamine. reticulatus or Hyoscamine niger, family: Solanaceae | Tropane alkaloids | Upregulate BDNF, because of the phosphorylation of CREB. Free radicals scavenging activity. Neurotrophic activity by increasing the phosphorylation of PI3K, Akt, GSK-3β and mTOR pathway. Decrease α-synuclein agereation. |
| 21| Asiatic acid | Centella asiatica Family: Apeacea | Triterpenoids | Triterpenoids Upregulate BDNF, because of the phosphorylation of CREB. Free radicals scavenging activity. Neurotrophic activity by increasing the phosphorylation of PI3K, Akt, GSK-3β and mTOR pathway. Decrease α-synuclein agereation. |
| 22| salvianolic acid | *Salvia miltiorrhiza* family: lamiaceae | Phenylpropanoid (coumarin) compounds | Protects DA neurons by reducing neuro-inflammation and increasing GDNF expression. Reduce caspase-3 and reduced cytochrome C activity Increases Bcl-x/Bax ratio. Free radicals scavenging activity. |
| 23| Fraxetin | Fraxinus bungeana, family: leaceae | Phenylpropanoid | Increase GSH level Reduce ROS mediated apoptosis |
| 24| MAM(2-methoxy-6-acetyl-7-methyljuglone) | Fallopia japonica. Family: polygonaceae | Naphthoquinone compounds | Inhibition phosphorylation of ERK1/2, JNK, and p38-MAPK and shows anti-apoptotic. |
1.7. Challenges with current synthetic treatment

Although there are a few medicines given to PD patients but none of them act on actual causal mechanism involved in the disorder. Coming to the mechanism symptoms, that occurs, dopamine loss is responsible for the motor symptoms of PD, that is why dopamine replacement therapies like tablets having carbidopa, levodopa and others are given to serve the replacement of depleted dopamine. Apart from the limitations that the gold standard levodopa does not act on the cause, another limitation that lies on long term administration the symptoms become the more severe. However the chronic use of L-dopa may turn into disabilities in motor symptoms like speech, gait, posture, etc. Another serious problem with L-dopa is that it increases neurodegeneration through oxidative stress. While levodopa possess all these problems, on the other hand sleep disturbances and cognitive problems such as confusion and hallucination arise from other PD medicines like MAO-B inhibitors, COMT inhibitors and anticholinergic drugs.

When drug therapy can no more provide symptomatic relief, surgeries like deep brain stimulations and lessional stimulations are opted by the physicians where areas like thalamus, globus pallidus are stimulated through low current. Out of these deep brain stimulation is more preferred due to its convenience where a medical device is implanted that sends electric impulses to required brain regions. Currently DBS in subthalamic nucleus (STN) and the globus pallidus internus (GPi) is the mostly opted surgery due to its great effectiveness. But again, DBS also has the same limitations in that it does not stop the disease progression and also does not prevent the worsening of symptoms. Lesion surgeries are also used which includes thalamotomy, pallidotomy, subthalamotomy, etc but their application is much less in the present time because of the risks associated with a surgical lesion another fact that has been known is that surgeries in PD lead to brain haemorrhage thereby enhancing the risk of morbidity and mortality. One approach that lacks side effects is rehabilitation therapy but it only improve functional ability. Rehabilitative therapy utilised to treat PD in order to improve functional capacity of in individuals by performing day to day exercise like stretching, muscle strengthening, postural exercises. It has been observed that physical exercise and treadmill training significantly improves motor functions in parkinsons patients. Non-conventional strategies like music and dance therapy also seen to be effective in management of affected motor activities.

However the current therapeutic regimen having some major limitations such as, It provides only symptomatic relief, fails to reduced disease progression, safety and life expectancy issues and cost of treatment is also more.

1.8. Natural products used in Parkinson’s disease therapeutics

Herbal plants have long been utilized to prevent and treat diseases. Nowadays, many people still rely on herbal neutraceuticals for their primary healthcare. More than 50% of the drugs currently in clinical application are of natural product origin. In the last few years, many researchers have investigated the role of various natural products and herbs in the treatment of PD. Some herbs have proved to be effective and more reliable than the usual synthetic drugs.

2. Conclusion

PD is one of the most common neurodegenerative diseases worldwide, and effective treatments for it are yet to be found the causes of PD is unknown, current treatments focus on managing patients’ symptoms and on increasing DA levels. Various types of important mechanisms with multiple factors are involved in the pathogenesis of PD these mechanisms may be targeted by diverse compounds from natural sources that exert anti-Parkinson effects via the modulation of the pathologic al pathways and/or factors involve. Thus, effective new treatment strategies for PD are urgently needed given the increasing number of PD patients worldwide. With further study of the pathogenesis of PD as well as deeper revealing of the pharmacological effects of various natural products, more and more monomer components derived from natural products are found to have anti-PD efficacy in vivo or vitro. However, many of these monomer components outlined above could not be directly used as drugs for the treatment of PD and related disorders. Therefore, we speculate that detailed investigations into the structure activity relationships of natural products outlined above may guide the design of novel therapeutic drugs in Parkinson’s disease which possess enhanced properties in vivo (e.g., ability to penetrate the blood brain barrier), but which retain the bioactivity characteristic of the natural product scaffold. Thus, these monomer components outlined above could represent starting points to the development of innovative anti-PD drugs.

3. Acknowledgment

The authors are thankful to the Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune (India) for unconditional support for the work.

4. Source of Funding

None.

5. Conflict of Interest

None,
References

1. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Synuclein in filamentous inclusions of Lewy bodies from Parkinson disease and dementia with Lewy bodies. Proc Natl Acad Sci 1998;95(11):6469–6473.

2. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257–1272.

3. Houghton PJ, Hooves MJ. Natural products and derivatives affecting neurotransmission relevant to Alzheimers and Parkinsons disease. Neurosignals. 2005;14(1-2):6–22.

4. Dauer W, Przedborski S. 2003.

5. Guiralt TR, Gonzales KK. Manganese-induced parkinsonism is not idiopathic Parkinsons disease: environmental and generic evidence. Toxicol Sci. 2015;146(2):204–212.

6. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Agid Y; 2004; & French Parkinson's Disease Genetics Study Group.

7. Gmez-Burgos E, Fernndez-Moriano C, Lozano R, Iglesias I, Gmez-Serranillos MP. Ginsenosides Rd and Re co-treatments improve rotenone-induced oxidative stress and mitochondrial impairment in SH-SHYSY neuroblastoma cells. Food and Chemical Toxicology. 2017;109:38–47.

8. Blandini F. Neural and immune mechanisms in the pathogenesis of Parkinsons disease. Journal of Neuroimmune Pharmacology. 2013;8(1):189–201.

9. Gmez-Glvez Y, Palomo-Garo C, Fernndez-Ruiz J, Garca C. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2016;64:200–208.

10. Li F, Zhu S, Wu C, Yan C, Liu Y, Shugan L. Neuroinflammation and cell therapy for Parkinsons disease. Front Biosci. 2011;13:1407–1427.

11. Francois A, Verite J, Bilan AR, Calon JT, Fauconneau F, et al.; 2016;.. InMolecules to Medicine with mTOR.

12. Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nature reviews Molecular biology. 2014;15(3):155–165.

13. Calkins MJ, Johnson DA, Townsend JA, Vargas MR, Dowell JA, et al. The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease. Antioxid Redox Signal. 2009;11(3):497–508.

14. Huang JY, Yuan YH, Yan JQ, Wang YN, Chu SF, et al. a bibenzyl compound isolated from Gastrodia elastata, protects PC12 cells against rotenone-induced apoptosis via activation of the Nrf2/ARE/HO-1 signaling pathway. ActaPharmacologicaSinica. 2016;37(6):731–731.

15. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, et al. Activation of microglia by human neuromelanin in NF-B dependent and involves p38 mitogen-activated protein kinase: implications for Parkinsons disease. FASEB J. 2003;17(3):500–502.

16. Corra SA, Eales KL. The role of p38 MAPK and its substrates in neuronal plasticity and neurodegenerative disease. J Signal Transduct. 2012;..

17. Duka T, Duka V, Joyce JN, Sidhu A. α-Synuclein contributes to GSK-β-catalyzed Tau phosphorylation in Parkinsons disease models. FASEB J. 2009;23(9):2820–2830.

18. Wu Y, Shang Y, Sun S, Liang H, Liu R. Erythropoietin prevents PC12 cells from 1-methyl-4-phenylpyridinium ion-induced apoptosis via the Akt/GSK-3β/caspase-3 mediated signaling pathway. Apoptosis. 2007;12(8):1365–1375.

19. Xia XG, Harding T, Wellier M, Bienenman A, Uney JB, et al. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson’s disease. Proc Natl Acad Sci 2001;98(18):10433–10438.

20. Kuan CY, Burke RE. Targeting the JNK signaling pathway for stroke and Parkinson's disease therapy. Current Drug Targets-CNS & Neurological Disorders. 2005;4(1):63–67.

21. Noda K, Kitumi T, Gai WP, Chegini F, Jensen PH, et al. Phosphorylated IB is a component of Lewy body of Parkinson disease. Biochemical Biophysical Res Commun. 2005;331(1):309–317.

22. Uberti D, Carsana T, Francisconi S, Toninelli GF, Canonico PL, Memo M. A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-B nuclear translocation. Biochemical pharmacology. 2004;67(9):1743–1750.

23. Berwick DC, Harvey K; 2012;..

24. Zhou T, Gu Z, Zhang X, Wang X, Li S, et al. Neuroprotective effects of ginsenoside Rg1 through the Wnt/β-catenin signaling pathway in both in vivo and in vitro models of Parkinson’s disease. Neuropharmacol. 2016;101:480–489.

25. Xilouri M, Vogiatzi T, Stefanis L. α-synuclein degradation by autophagic pathways: a potential key to Parkinsons disease pathogenesis. Autophagy. 2008;4(7):917–919.

26. Xilouri M, Stefanis L; 2011;.. Expert reviews in molecular medicine.

27. Shahed J, Jankovic J. Motor symptoms in Parkinson's disease. Handbook Clin Neurol. 2007;1:329–329.

28. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–474.

29. Burke T, Galvin M, Maguire S, Pender N, Hardiman O. The impact of cognitive and behavioural change on quality of life of caregivers and patients with ALS and other neurological conditions. Amyotrophic Lateral Sclerosis: Understanding and Optimizing Quality of Life and Psychological Well-Being. 2018;9:151–151.

30. Fox SH, Katzenschlager R, Lim SY, Barton B, Bie RMD, Seppi K. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Movement Disorders. 2018;33(8):1248–1266. & Movement Disorder Society Evidence-Based Medicine Committee.

31. A Review on Pharmacological Treatment of Idiopathic Parkinsons Disease. J Neurol Disord. 2017;5(347).

32. Kakkar AK, Dahiya N. Management of Parkinson s disease: Current and future pharmacotherapy. Eur J Pharmacol. 2015;5:74–81.

33. Sweeney P, Park H, Baumann M, Dunlop J, Frydman J, et al. Protein misfolding in neurodegenerative diseases: implications and strategies. Translational neurodegeneration. 2017;6(1):6–6.

34. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Sci. 2004;304(5674):1158–1160.

35. Robinson, Philip A. Protein stability and aggregation in Parkinson's disease. Biochemical J. 2008;413:1–13.

36. Gandhi S, Wood NW. Molecular pathogenesis of Parkinson’s disease . 2005;..

37. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson’s disease pathology spread. Nature Rev Neurosci. 2008;9(10):741–741.

38. Kalia LV, Kalia SK. α-Synuclein and Lewy pathology in Parkinson’s disease. Curr Opinion Neurol. 2015;28(4):375–381.

39. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, et al. α-Synuclein in Lewy bodies. Nature. 1997;388:839–839.

40. Cheng F, Vivacqua G, Yu S. The role of alpha-synuclein in neurotransmission and synaptic plasticity. J Chem Neuroanat. 2011;42(4):242–248.

41. Caughey B, Lansbury PT; 2003;..

42. Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B. α-Synuclein degradation::pathology, mitochondrial dysfunction and neuroinflammation in Parkinsons disease. Neuropharmacol. 2018;109:249–257.

43. Lee HC, Wei YH. Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int J Biochem Cell Biol. 2005;37(4):822–834.

44. Langston JW, Ballard P, Tetrad JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Sci. 1983;219(4587):979–980.

45. Przedborski S, Vila M. MPTP: a review of its mechanisms of neurotoxicity. Clin Neurosci Res. 2001;1(6):407–418.
47. Giordano S, Lee J, Darley-Usmar VM, Zhang J. Distinct effects of rotenone, 1-methyl-4-phenylpyridinium and 6-hydroxydopamine on cellular bioenergetics and cell death. PloS one. 2012;7(9):e44610–e44610.

48. Meredith GE, Rademacher DJ. MPTP mouse models of Parkinson’s disease: an update. Journal of Parkinson’s disease. 2011;1(1):19–33.

49. Zang LY, Misra HP. Generation of reactive oxygen species during the monoamine oxidase-catalyzed oxidation of the neurotoxicant, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. J Biol Chem. 1993;268(22):16504–16512.

50. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nature Reviews Neuroscience. 2006;7(3):207–207.

51. Vila M, Przedborski S. Neurological diseases: Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci. 2003;4(5).

52. Xiong N, Long X, Xiong J, Mia J, Chen C, et al. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson’s disease models. Critical reviews in toxicology. 2012;42(7):613–632.

53. Thyagarajan D, Bressman S, Bruno C, Przedborski S, Shanske S, et al. A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann Neurol. 2000;48(5):730–736.

54. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson’s disease. Journal of Parkinson’s disease. 2013;3(4):461–491.

55. Meiser J, Weindl D, Hiller K. Complexity of dopamine metabolism. Cell Communication and Signaling. 2013;11(1).

56. Gangemi S, Gofta E, Costa C, Teodoro M, Briguiglio G, et al. Occupational and environmental exposure to pesticides and cytokine pathways in chronic diseases. Int J Molecular Med. 2016;38(4):1012–1020.

57. Saltzart MT, Dinis-Oliveira RJ, Bastos MDL, Tsatsakis AM, Duarte JA, Carvalho F. Pesticides exposure as etiological factors of Parkinson’s disease and other neurodegenerative diseases—a mechanistic approach. Toxicology letters. 2014;230(2):85–103.

58. Perfeito R, Cunha-Oliveira T, Rego AC. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease—resemblance to the effect of amphetamine drugs of abuse. Free Radical Biol Med. 2012;53(9):1791–1806.

59. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nature Rev Drug Discovery. 2004;3(3):205–205.

60. Zuo L, Motherwell MS. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson’s disease. Gene. 2013;532(1):18–23.

61. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Sci. 2004;304(5674):1158–1160.

62. Rego AC, Oliveira CR. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochemical Res. 2003;28(10):1563–1574.

63. Mcgeer PL, Itagaki S, Akiyama H, Mcgeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol: Official J Am Neurol Assoc Child Neurol Soc. 1988;24(4):574–576.

64. Tansey MG, Mc coy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol. 2007;208(1):1–11.

65. Saito K, Winner B, Carson CT, Collier JG, Boyer L, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 2007;137(1):47–59.

66. Su X, Maguire-Zeiss KA, Giuliani R, Prifi L, Venkatesh K, Fedoroff HJ. Synuclein activates microglia in a model of Parkinson’s disease. Neurobiol Aging. 2008;29(11):1690–1701.

67. Codolo G, Plotgeher N, Pozzobon T, Bruncle M, Tesari I, et al. Triggering of inflammasome by aggregated-synuclein, an inflammatory response in synucleinopathies. PloS One. 2013;8(1). e55375.

68. Fonseca ACD, Matias D, Garcia C, Amaral R, Geraldo LH, et al.; 2014.

69. Fonseca ACD, Matias D, Garcia C, Amaral R, Geraldo LH, et al.; 2014.

70. Lim KL. Molecular events underlying Parkinsons disease—an interwoven tapestry. Front Neurol. 2013;4.

71. Ghuvasi S, Shojaii S, Yeganeh B, Ande SR, Jangamreddy JR, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Progress Neurobiol. 2014;112:24–49.

72. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci. 2005;28:57–87.

73. Diaz NL, Waters CH. Current strategies in the treatment of Parkinsons disease and a personalized approach to management. Expert Rev Neurotherapeutics. 2009;9(12):1781–1789.

74. Mercuri NB, Bernardi G. The magicof L-dopa: why is it the gold standard Parkinson’s disease therapy. Trends Pharmacol Sci. 2005;26:341–344.

75. Odin P, Wolters E, Antonini A. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion. Neurol Sci. 2008;29(5):387–388.

76. Cao XB, Guan Q, Xu Y, Wang L, Sun SG. Mechanism of overactivation in direct pathway mediated by dopamine D receptor in rats with levodopa-induced dyskinesia. Neurosci Bull. 2006;22(3):159–164.

77. Pahwa R, Lyons KE. Levodopa-related wearing-off in Parkinson’s disease: identification and management. Curr Med Res Opin. 2009;25(4):841–849.

78. Yuan H, Zhang ZW, Liang LW, Shen Q, Wang XD, et al. Treatment strategies for Parkinsons disease. Neurosci Bull. 2010;26(1):66–76.

79. Little S, Pogosyan A, Neal S, Zavala B, Ziruo L, et al. Adaptive deep brain stimulation in advanced Parkinson disease. An Neurology. 2013;74(3):449–457.

80. Poewe W, Seppi K, Tanner CM, Halliday GM, Bundrin P, et al. Nature Rev Dis Primers. 2017;3:17013–17013. Parkinson disease.

81. Fox SH, Katzschnegler R, Lim SY, Barton B, Bie RMD, Seppi K. Movement Disorder Society Evidence-Based Medicine Committee. (2018). International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Movement Disord. 2018;33(8):1248–1266. Movement Disorders.

82. Rocchi L, Carlson-Kuhta P, Chiari L, Burchiel KJ, Hogarth P, et al. Effects of deep brain stimulation in the subthalamic nucleus or globus pallidus internus on step initiation in Parkinson disease. Journal Neurosurg. 2012;117(6):1141–1149.

83. Tsai ST, Lin SH, Chou YC, Pan YH, Hung HY, et al. Prognostic factors of subthalamic stimulation in Parkinsons disease: a comparative study between short-and long-term effects. Stereotact Funct Neurosurg. 2009;87(4):241–248.

84. Krak P, Martinez-Fernandez R, Alamdo MD, Obeso JA. Current applications and limitations of surgical treatments for movement disorders. Mov Disord. 2017;32(1):36–52.

85. Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol. 2009;8(1):67–81.

86. Abbruzzese G, Marchese R, Avanzino L, Pelosin E. Rehabilitation for Parkinson’s disease: Current outlook and future challenges. Parkinsonism Relat Disord. 2016;22:60–64.

87. Tomlinson CL, Patel S, Meek C, Herd CP, Clarke CE, et al. Physiotherapy versus placebo or no intervention in Parkinson’s disease. Cochrane database of systematic reviews ; 2013..

88. Clarke CE, Patel S, Ives N, Rick CE, Dowling F, et al. Physiotherapy and occupational therapy vs no therapy in mild to moderate Parkinson disease: a randomized clinical trial. JAMA Neurol. 2016;73(3):291–299.

89. Mehlholz J, Kugler J, Storch A, Pohl M, Hirsch K, et al. Treadmill training for patients with Parkinson’s disease. Cochrane Database Systematic Rev. 2015(9).
90. Li F, Harmer P, Fitzgerald K, Eckstrom E, Stock R, et al. *N England J Med.* 2012;366:511–519.
91. Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Limitations of current Parkinson’s disease therapy. *Ann Neurol: Official J Am Neurological Assoc Child Neurol Soc.* 2003;53(S3):3–15.
92. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. *Life Sci.* 2005;78(5):431–441.

**Author biography**

**Rohit R Doke** Student

**Prajakta A Pansare** Student

**Shivani R Sainani** Student

**Vrushali M Bhalchim** Student

**Ketki R Rode** Student

**Shivani R Desai** Assistant Professor

---

**Cite this article:** Doke RR, Pansare PA, Sainani SR, Bhalchim VM, Rode KR, Desai SR. Natural products: An emerging tool in parkinson’s disease therapeutics. *Indian J Neurosci* 2019;5(3):95-105.